In the touchOPHTHALMOLOGY Fall issue of US Ophthalmic Review, Dr Alay Banker published an interesting review on “Emerging Treatments for Non-infectious Uveitis”. In this interview at AAO 2018, he discusses the side effects associated with steroidal treatments and how this impacts patient adherence. It is hoped that emerging non-steroidal drugs can alleviate some of these issues. Dr Banker describes the promising discovery of new pathways to target retinal diseases and new cost-effective drugs. He also points out that, unfortunately, the advent of biosimilars in retinal diseases is lagging behind that of other therapeutic areas, particularly in the case of biosimilar anti-vascular endothelial growth factor (anti-VEGF) and biosimilar biologics. Finally, Dr Banker highlights some of the topics he has found most interesting at this year’s AAO meeting, including new imaging techniques and drug delivery systems.
Questions:
1. Please give a brief introduction to your article from our Fall issue of US Ophthalmic Review, ‘Emerging Treatments for Non-infectious Uveitis’. (0:11)
2. What do you think are the most promising areas of research or therapies in this area for the future? (1:16)
3. What are your key highlights from this year’s American Association of Ophthalmology (AAO) meeting? (2:18)
Speaker disclosures: Alay Banker has nothing to disclose in relation to this interview.
Filmed at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting, Chicago, IL, US, 27–30 October 2018.
